Genmab A/S

NASDAQ:GMAB

Biotechnology

Healthcare
$50.97 -0.47%

-$0.12 today

Market cap
$31.43B
Beta
0.68
P/E (TTM)
18.7
EPS (TTM)
$13.36
52W Low $20.23High $35.43

Volume 2.96M

Average 1.85M

GMAB Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Genmab A/SNASDAQ: GMAB

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) declines year over year

Q2 FY2026 weighted avg shares (diluted) of 617.11M shares fell 0.5% year over year. Sequentially, it fell 3.4% from the prior quarter. Over 3 fiscal years it compounded at -1.7% a year.

Context

  • Weighted avg shares (diluted) increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
617.11M-3.4% QoQ
Last fiscal yearDec 2025
626.92M-3.0% YoY
LTMJun 2026
637.25M— YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.5%——
1 year-3.0%——
3-year CAGR-1.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
626.92M USD
Year-over-year change
—

Weighted Avg Shares (Diluted) vs competitors

How GMAB compares with its peers on the latest reported figures

  • GMAB's LTM Jun 2026 weighted avg shares (diluted) of 637.25M shares is the highest of the 11 companies compared; the peer median is 163.96M shares.
  • Over three fiscal years its annual growth of -1.7% compares with a peer median of +3.9%.
GMAB Competitors Peer median
Weighted Avg Shares (Diluted) for GMAB and competitors
Company Period LTM YoY 3-year CAGR
GMABGenmab A/SLTM Jun 2026637.25M —-1.7%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026432.9M +30.6%+30.9%
EXELExelixis, Inc.LTM Jul 2026271.85M -6.1%-4.6%
BNTXBioNTech SELTM Jun 2026247.64M +2.5%-1.1%
INCYIncyte CorporationLTM Jun 2026205.31M +3.9%-3.6%
LEGNLegend Biotech CorporationLTM Sep 2026189.27M +2.9%+5.0%
ADCTADC Therapeutics S.A.LTM Mar 2026138.66M +34.3%+17.6%
RCUSArcus Biosciences, Inc.LTM Jun 2026116.35M +19.9%+14.3%
CGENCompugen Ltd.LTM Mar 202694.08M +4.2%+2.7%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
ALXOALX Oncology Holdings Inc.LTM Mar 202653.9M +2.3%+9.7%
Peer median (excluding GMAB) 163.96M+3.4%+3.9%

Competitors are the stored peer set for GMAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · DKK
FY2022
Dec 2022 · DKK
FY2023
Dec 2023 · DKK
FY2024
Dec 2024 · DKK
FY2025
Dec 2025 · USD
Revenue8.42B14.51B16.47B21.53B3.72B
Cost of Revenue00226M985M309.24M
Gross Profit8.42B14.51B16.25B20.54B3.41B
Gross Margin100.0%100.0%98.6%95.4%91.7%
Research & Development4.18B5.56B7.63B9.75B1.56B
Selling, General & Admin1.28B2.68B3.3B3.79B602.47M
Operating Expenses5.46B8.24B10.93B13.84B2.16B
Depreciation & Amortization248.99M362M293.62M413M71.06M
EBITDA4.18B7.35B6B9.7B1.34B
EBITDA Margin49.7%50.6%36.4%45.0%35.9%
Operating Income2.95B6.27B5.32B6.7B1.25B
Operating Margin35.1%43.2%32.3%31.1%33.6%
Interest Income197M324M939M995M138.11M
Interest Expense13M21M27M120M61.05M
Other Income / Expenses965M678M316M2.46B(46.04M)
Income Before Tax3.92B6.95B5.64B9.16B1.2B
Pre-Tax Margin46.5%47.9%34.2%42.6%32.4%
Income Tax Expense961M1.49B1.29B1.32B241.19M
Net Income2.96B5.45B4.35B7.84B963.76M
Net Margin35.1%37.6%26.4%36.4%25.9%
EPS (Basic)4.528.346.6012.141.55
EPS (Diluted)4.488.266.6012.141.54
Weighted Avg Shares653.96M653.87M659.15M646.33M621.51M
Weighted Avg Shares (Diluted)660.46M660.1M659.15M646.33M626.92M

Genmab A/S

NASDAQ:GMAB

Intrinsic Alpha fair value

Locked

Current Price

$50.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.